CAPR240517C5000
- 1.20
- 0.000.00%
Capricor Therapeutics Newsroom
Capricor Therapeutics (NASDAQ:CAPR) Shareholder Returns Have Been Stellar, Earning 113% in 5 Years
PTC Therapeutics Rallies 18% on EU Authorization Update for Translarna
Express News | Capricor Therapeutics Inc : Oppenheimer Initiates Coverage With Outperform Rating; Target Price $14
Capricor Therapeutics Initiated at Outperform by Oppenheimer
Capricor Therapeutics Initiated at Outperform by Oppenheimer
Oppenheimer Initiates Coverage On Capricor Therapeutics With Outperform Rating, Announces Price Target of $14
Oppenheimer analyst Leland Gershell initiates coverage on Capricor Therapeutics with a Outperform rating and announces Price Target of $14.
Capricor Therapeutics: A Buy Rating Backed by Financial Stability and Promising DMD Treatment Developments
Expert Ratings For Capricor Therapeutics
During the last three months, 5 analysts shared their evaluations of Capricor Therapeutics (NASDAQ:CAPR), revealing diverse outlooks from bullish to bearish.The table below summarizes their recent rat
Capricor Therapeutics Is Maintained at Buy by Ladenburg Thalmann
Capricor Therapeutics Is Maintained at Buy by Ladenburg Thalmann
Ladenburg Thalmann Maintains Buy on Capricor Therapeutics, Raises Price Target to $25
Ladenburg Thalmann analyst Aydin Huseynov maintains Capricor Therapeutics (NASDAQ:CAPR) with a Buy and raises the price target from $24 to $25.
Capricor Therapeutics Price Target Maintained With a $8.00/Share by Cantor Fitzgerald
Capricor Therapeutics Price Target Maintained With a $8.00/Share by Cantor Fitzgerald
Capricor Therapeutics | 10-Q: Quarterly report
Express News | HC Wainwright & Co. Reiterates Buy on Capricor Therapeutics, Maintains $40 Price Target
Capricor Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/14/2024 684.31% HC Wainwright & Co. → $40 Reiterates Buy → Buy 04/25/2024 684.31% HC Wainwright & Co. →
Analysts' Top Healthcare Picks: Stereotaxis (STXS), Capricor Therapeutics (CAPR)
Capricor Therapeutics: A Strong Buy on Positive Financial Outlook and Regulatory Advancements
Earnings Call Summary | Capricor Therapeutics(CAPR.US) Q1 2024 Earnings Conference
The following is a summary of the Capricor Therapeutics, Inc. (CAPR) Q1 2024 Earnings Call Transcript:Financial Performance:Capricor Therapeutics reported a Q1 cash balance of around $39.9 million, up
Capricor Therapeutics Inc (CAPR) Q1 2024 Earnings Call Transcript Highlights: Strategic ...
Capricor Therapeutics (CAPR) Reports Q1 Loss, Misses Revenue Estimates
Capricor Therapeutics Expects Available Cash & Equivalents To Be Sufficient To Cover Anticipated Expenses And Capital Requirements Into Q1 Of 2025
Capricor Therapeutics Expects Available Cash & Equivalents To Be Sufficient To Cover Anticipated Expenses And Capital Requirements Into Q1 Of 2025
Earnings Flash (CAPR) CAPRICOR THERAPEUTICS Posts Q1 Revenue $4.9M, Vs. Street Est of $9.7M
04:13 PM EDT, 05/13/2024 (MT Newswires) -- Earnings Flash (CAPR) CAPRICOR THERAPEUTICS Posts Q1 Revenue $4.9M, vs. Street Est of $9.7M